The test uses proprietary peptide analogs to detect overexpression of a peptide construct that binds to cancer cell membranes in urine or blood samples.
The test will combine Qiagen's QuantiFeron (interferon-gamma release assay) technology with DiaSorin's Liaison automated analyzers.
In a tie-up with an asbestos workers' trade union, Owlstone Medical aims to analyze chemicals in the breath of people with historical exposure to asbestos.
Biotage will provide systems and consumables from its analytical chemistry portfolio to be sold by Yingsheng under its own brand.
Caris will use its whole-transcriptome sequencing assay and Molecular Intelligence Trials service to identify patients for a phase II clinical trial.
The companies will work together first to develop a companion diagnostic for Bayer's TRK inhibitor larotrectinib, with opportunities to expand to other drugs and drug candidates thereafter.
The firms anticipate discovering and validating a biomarker signature, or signatures, for earlier detection of pulmonary hypertension and its subtypes.
The companies will pair sequencing with genotype-phenotype matching and analytics in pursuit of wider access to precision medicine and faster, more accurate diagnoses.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
The test uses machine learning algorithms to assess predictive biomarkers and electronic health record information to identify progressive kidney disease.